Caladrius Biosciences Explained
Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]
Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.
In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics.[5]
Cardiovascular disease
In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction.[6]
The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients. [7]
Notes and References
- Web site: Editorial . Reuters . CLBS.PH - Caladrius Biosciences Inc Profile Reuters . www.reuters.comundefined . en.
- https://www.bloomberg.com/news/videos/b/e2f0f645-6d45-4ad5-8737-f7b1334f974a NeoStem CEO Discusses Adult Stem Cell Therapies
- Web site: Caladrius Biosciences - Consensus Indicates Potential 316.7% Upside - DirectorsTalk Interviews. 2021-05-03. en-GB.
- https://www.sec.gov/cgi-bin/browse-edgar?company=neostem&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany EDGAR Search Results – Neostem
- https://www.globenewswire.com/en/news-release/2022/09/15/2516989/18623/en/Caladrius-Biosciences-and-Cend-Therapeutics-Announce-Closing-of-Merger-and-the-Emergence-of-Lisata-Therapeutics.html Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
- https://clinicaltrials.gov/ct2/show/NCT01495364 NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)
- PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. Circulation Research. 120. 2. 324–331. Arshad A. Quyyumi. 10.1161/CIRCRESAHA.115.308165. 27821724. 2017. 5903285.
